相关实验视频
Updated: May 31, 2025
08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
67.1K
聚氨酸B4通过抑制巨细胞中CD1d依赖的NLRP3炎症酶激活来缓解DSS诱导的大肠炎
1Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116001, China.
International immunopharmacology
|January 24, 2025
概括
聚氨酸B4 (PB4) 通过抑制巨细胞中的NLRP3炎症酶,有效治疗性结肠炎 (UC). 这种植物性化合物向CD1d,为结肠炎提供了一种新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 构成了全球卫生挑战,需要新的抗结肠炎疗法.
- 在巨细胞中NLRP3炎症酶抑制是UC的有希望的治疗途径.
- 植物衍生化合物Pulchinenoside B4 (PB4) 具有抗炎性质.
研究的目的:
- 为了研究PB4在缓解硫酸 (DSS) 诱导的大肠炎方面的疗效.
- 为了确定PB4是否抑制巨细胞中的NLRP3炎症酶,作为其作用机制.
- 为了阐明PB4所准的分子途径.
主要方法:
- 在C57BL/6小鼠和NLRP3淘汰小鼠中的DSS诱导性结肠炎模型.
- 隔离肠道巨细胞和上皮细胞进行体外分析.
- 生物层干扰 (BLI) 和细胞热迁移 (CETSA) 测试以确定PB4的分子标和机制.
- 巨细胞特定的CD1d消耗模型.
主要成果:
- 在DSS诱导的大肠炎的野生类型小鼠中,PB4显示出显著的抗炎作用.
- 在NLRP3淘汰赛小鼠中,PB4的保护作用减弱.
- 在结肠巨细胞中,PB4抑制了NLRP3炎症酶激活,但不能抑制肠道上皮细胞.
- 发现PB4可以向CD1d,调节AKT-STAT1-PRDX1-NF-κB通路.
- 巨细胞特异性CD1d耗尽逆转了PB4的保护作用.
结论:
- PB4通过抑制巨细胞中的NLRP3炎症酶激活来改善DSS诱导的大肠炎.
- PB4的机制包括向CD1d和调节AKT-STAT1-PRDX1-NF-κB信号通路.
- 这些发现支持开发针对UC的CD1d/NLRP3向疗法以及PB4的临床使用.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:17Drugs for Treatment of Diarrhea-Predominant IBS
145
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
145
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95